INSULET CORP
PODDNASDAQTrading Snapshot
- Day Range
- $143.28 – $147.03
- 52-Week Range
- $126.40 – $354.88
- Volume
- $5.48B
- Avg Volume
- $4.75B
- Shares Outstanding
- 69.3M
- Next Earnings
- Oct 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.71B
- Last Q Revenue
- $802M
- P/E Ratio
- 26.1
- P/S Ratio
- 3.2x
- EPS (TTM)
- $5.35
- Dividend Yield
- —
Why Investors Own PODD
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About INSULET CORP
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
Insulet (PODD) Stock Looks Undervalued As The Market Stays Cautious
Insulet stock has fallen sharply over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading below what the underlying business may be worth. Over the past 12 months, Insulet has declined 54.1%, which means the market has already priced in a lot of pessimism. The recent cut to full year revenue growth expectations after an earnings beat can weigh on sentiment, while any renewed confidence in Insulet's long...
Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.
Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says
Insulet's (PODD) execution challenges in serving Type 2 diabetes patients, upcoming competition in p
Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145
Leerink Partners analyst Mike Kratky downgrades Insulet (NASDAQ:PODD) from Outperform to Market Perform and lowers the price target from $247 to $145.
TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144
TD Cowen analyst Mathew Blackman maintains Insulet (NASDAQ:PODD) with a Hold and lowers the price target from $294 to $144.